Peptides sold for growth hormone get talked about as one shelf, and the mechanism row of this site’s matrix does not agree. Of the 5 molecules recorded here, 4 are recorded as GHRH analog and 1 as ghrelin mimetic. That is a difference about which receptor a molecule arrives at, and it was settled in the papers that named these compounds. It is also invisible on a price list: it is not a field this site records from a seller page, and it is not something a listing title has to say. What the listings do instead is respect it — every one of them that sells two of these molecules at once takes one from each side of the split.
Sermorelin, Tesamorelin, CJC-1295 (no DAC) and CJC-1295 + DAC all carry the same recorded mechanism, and each of those 4 cells is traced to a document. What the phrase means is at its plainest in the oldest of them, which describes sermorelin by giving its sequence rather than its category.
Synthetically produced GRF1-29 (Sermorelin) has an amino acid composition identical to the N-terminal 29 amino acids sequence of the natural hypothalamic GHRH1-44
An analog of the hormone, then — the first twenty-nine amino acids of a forty-four-amino-acid hypothalamic peptide, arriving at the receptor the body’s own GHRH arrives at. The other three in this group are recorded under the same class for the same reason. What separates them is not the door they knock on; it is how long they last once they are through it, which is the next section but one.
There are two classes in this column and no third, which is what makes it a line rather than a spectrum. A class is also not a licence, a safety finding or a dose: it is one row of the matrix, and the other 4 disagree with it constantly.
Ipamorelin is the exception, and the paper that introduced it did not leave the question open. Its authors ran the compound against antagonists of both receptor systems and reported which one answered.
A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor.
The later paper this site cites for the cell says the same thing in the vocabulary the cell uses, describing ipamorelin as “ipamorelin, a selective growth hormone secretagogue and agonist of the ghrelin receptor”. Ghrelin is a stomach hormone; the receptor it acts on is not the GHRH receptor, and a molecule that reaches growth hormone through it is doing a different thing on the way, whatever the shelf it is sold from says.
That is the whole of the difference this page is about, and it is also the reason the two are so often sold together rather than instead of each other. What the literature records about combining them is on sermorelin vs ipamorelin, which takes one such pair in detail; what the sellers do with it is below.
Here is what makes the split worth a page rather than a footnote. 5 of the 18 priced listings this site has read name more than one of these 5 molecules, across 3 of the 14 sellers on the roster — and 5 of those 5 put one molecule from each side of the split into the same product. Not one of them pairs two molecules from the same class.
None of that is in the titles. What these records hold for a listing is its name, its figure and the molecules the figure buys — there is no mechanism field on a seller record here, and nothing in them says a seller ever mentions one. But the pattern in what they buy is exact, and it is the pattern the literature would predict from two different receptors rather than one.
Listings naming more than one of the 5
5 of 18
From 3 of the 14 sellers on this roster.
Of those, pairing across the two classes
5 of 5
The empty part of this bar is the number that stay inside one class, and it is zero.
Of those, stating what dose the money buys
0 of 5
None of them. The pairing is named; the amount of either molecule in it is not.
Of those, saying which CJC-1295 form is inside
3 of 5
2 name a CJC-1295 product without saying which of this site's two records it is.
Counted from the 18 priced listings behind the board, each read off the seller’s own page and dated. The per-seller working is on the seller records.
A class is a weak predictor here, and the honest thing is to say so on the page that draws the line. Inside the group of 4, the recorded half-lives run from 10–20 min for Sermorelin to 5.8–8.1 days for CJC-1295 + DAC — a factor of somewhere between 418 and 1166, between two molecules the mechanism row files together.
Both ends of that span carry a document, which is why the sentence above is allowed to state it. The ratio is a division of two sourced records and nothing else. The two records between them are the ones this site cannot yet trace: Tesamorelin’s half-life is recorded as 26–38 min [needs citation] and CJC-1295 (no DAC)’s as ~30 min [needs citation], and both are among the open items listed on the sources page.
The other rows disagree with the class too. The regulatory record splits this same group of 4 into 3 on its own, and which of these is FDA approved? takes that column the way this page takes the mechanism one. Nothing on this page says a molecule in either class is safer, stronger or better suited to anybody — that is a clinician’s judgement about a person, and this is a row in a table.
Every value here is read out of the same records the matrix prints, and the marker beside one is the site saying it cannot show you a document for it.
Every pharmacological figure on this page is traced to a document below or marked as untraced. The quotations above are printed from the abstracts those documents publish, not from summaries of them, and each is attributed to the document the cell it belongs to actually cites.
Citation status, counted from the records behind this page rather than typed: 3 of 21 pharmacological figures on it are recorded in this site’s data but not yet traced to a published source, and they are marked [needs citation] where they appear. Where the writing below restates one of those figures, it rests on the same unsourced record. The open sourcing work is listed in the repository’s content to-do. This line counts itself down as sources land.
8 documents are cited on this page, listed in the order the figures above rely on them. Each carries the date printed on the document itself, which is not the date it was read and not the date in its address.
The board below is every listing in these records that buys Ipamorelin. It is the same set as the pairings above, because none of the figures this site holds for that molecule buys it on its own. Each figure carries the qualifier that makes it mean something: what kind of number it is, what period it is charged for, what dose it buys, and the day it was read. Nothing here names a cheapest. The full roster of 18 listings across 14 sellers is on the home page.
The board scrolls sideways; the seller column and the button column both stay put.
| Seller | What the figure buys | Figure | What it is | Charged | Dose | Go |
|---|---|---|---|---|---|---|
| ElitePhysiqMD | TesamorelinIpamorelin“Tesamorelin / Ipamorelin” | $274.50Checked September 2026 | standing rate | per month | dose not stated | Open listing → |
| Ipamorelin“CJC-1295 + Ipamorelin” — also buys CJC-1295, with or without DAC not stated | $315.00Checked September 2026 | standing rate | per month | dose not stated | ||
| Longevixx | Ipamorelin“CJC-1295 / Ipamorelin” — also buys CJC-1295, with or without DAC not stated | from $329Checked September 2026 | floor | per month | dose not stated | Open listing → |
| TesamorelinIpamorelin“Tesamorelin / Ipamorelin” | from $349Checked September 2026 | floor | per month | dose not stated | ||
| Youth & Soul | SermorelinIpamorelin“Growth Hormone Optimization” — also buys NAD+ sublingual tablets (250mg); Methylene Blue; IGF-1 & hormone panel blood work review; physician monitoring & dose optimization | $149Checked September 2026 | standing rate | per month | dose not stated | Open listing → |
Read off each seller’s own page and dated in the row. Nothing here is scored or ranked; the ordering is the order the records are written in lib/providers.ts.
The list that follows is drawn from all 5 molecules rather than from the board above, so it is wider by 1 record: a seller carrying more than one of these molecules whose figures this site declines to publish, with the reason on its own record.
4 of this site’s 14 seller records carry more than one of Sermorelin, Tesamorelin, Ipamorelin, CJC-1295 (no DAC), CJC-1295 + DAC — which is the only reason they are listed here rather than everyone we have read. 0 of them pay us a commission; 4 do not. Which is which is on each seller’s own record and, counted, on the disclosure page. Their figures, with every qualifier attached, are in the board above.
Prices four listings across three of these molecules on one catalogue page and states a dose on none of them. Tesamorelin alone and tesamorelin with ipamorelin carry the identical figure, which is the clearest thing on the page: adding a second molecule changes the price by nothing. The catalogue also prints “Save 10% with subscription” beside the figures.
Every figure on this catalogue is a floor — the page prints “from” in front of all of them — and none states a dose, so the gaps between the four are gaps between starting points, not between what anyone pays. The CJC-1295 listing is sold only as a pairing and never says which form of CJC-1295 it contains.
The strongest single illustration on this site of the problem it exists to describe: sermorelin and tesamorelin are offered side by side in one medication picker, at the same struck-through figure and the same discounted figure, over the same supply. Two molecules whose recorded half-lives differ by roughly an order of magnitude, priced as though the choice between them were a flavour.
Sells a tier, not a drug. The figure buys sermorelin and ipamorelin together with the other items listed against it, so it is not a price for either peptide and this site does not use it as one. Neither molecule is offered on its own anywhere on the page.